Compare Amgen, Inc. (AMGN) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Hewlett Packard Enterprise Co — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Hewlett Packard Enterprise Co trades at $47.9 (market cap $64.28B). The key difference: Amgen, Inc. is far larger — about 3.1× Hewlett Packard Enterprise Co's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | HPE | |
|---|---|---|
Market Cap | $196.12B | $64.28B |
Sector | Health | Technology |
52-Week High | $388.16 | $56.14 |
52-Week Low | $271.18 | $19.81 |
Enterprise Value | $241.41B | $80.23B |
Dividend Yield | 2.77% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HPE trades at $48.50, down 1.22% on the day, with strong technical momentum showing a bullish moving average signal despite neutral oscillators. The company demonstrates robust revenue growth, reaching $34.30 billion in 2025, with earnings consistently beating expectations in recent quarters. Analyst consensus remains positive with a $69.69 price target, representing 44% upside potential. Recent news highlights HPE's strategic positioning in AI infrastructure with a nearly $6 billion backlog and benefits from Juniper Networks acquisition driving networking revenue growth.
HPE presents a compelling investment case with strong AI-driven growth prospects and improving fundamentals, though investors face risks from elevated valuation multiples and competitive pressures. The stock's technical setup supports further upside toward resistance levels near $50-52, while fundamental improvements in margins and cash flow generation provide support for long-term growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
